Posted by Michael Wonder on 24 Nov 2022
Outcome in relation to discussion of COVID-19 oral treatments – November 2022 PBAC meeting
24 November 2022 - A PBAC outcome in relation to discussion of COVID-19 oral treatments at the November 2022 meeting has been published.
At its November 2022 meeting, the PBAC considered several aspects of the PBS listings of the COVID19 oral ant-ivirals, molnupiravir (Lagevrio) and nirmatrelvir and ritonavir (Paxlovid).
